Indication
Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma
1 clinical trial
1 product
Clinical trial
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasStatus: Recruiting, Estimated PCD: 2024-12-01
Product
DR-01